ARWR vs CUBE · rev $829.4M vs P/E 25, rev $1.07B
Arrowhead Pharmaceuticals Inc (ARWR) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
ARWR currently screens at market cap $10.59B. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the ARWR and CUBE stock pages for the full models.
Not investment advice.